CA
NZ
UK
AU
IND
US
Shares of Fulcrum Therapeutics, Inc. (Nasdaq: FULC) closed at $3.14 on June 2, 2026, a loss of $3.28 or 51.09% onVolumeof 32.77 million shares. Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum is a clinical-stage biopharmaceutical company developing small molecule medicines that modulate …
Shares of Editas Medicine, Inc. (Nasdaq: EDIT) closed at $2.82 on June 2, 2026, a loss of $0.52 or 15.57% on volume of 3.84 million shares. Founded in 2013 and headquartered in Cambridge, Massachusetts, Editas is a clinical-stage biotechnology company pioneering in vivo genomic …
Shares of Context Therapeutics Inc. (Nasdaq:CNTX) closed at $2.42 on June 2, 2026, a loss of $0.37 or 13.26% onVolumeof 537,610 shares. Incorporated in 2015 and headquartered in Philadelphia, Pennsylvania, Context Therapeutics is a clinical-stage biopharmaceutical company focused on advancing T cell engaging bispecific …
Shares of Canton Strategic Holdings, Inc. (Nasdaq: CNTN) closed at $2.37 on June 2, 2026, a loss of $0.44 or 15.66% onVolumeof 2.54 million shares. Headquartered in Red Bank, New Jersey, Canton Strategic Holdings is a Nasdaq-listed company operating at the intersection of institutional …
Shares of Shattuck Labs, Inc. (Nasdaq: STTK) closed at $4.87 on June 2, 2026, a loss of $0.78 or 13.81% onVolumeof 831,200 shares. Founded in 2016 and headquartered in Austin, Texas, Shattuck Labs is a clinical-stage biotechnology company developing novel biologic therapies for inflammatory …
Shares of Cue Biopharma, Inc. (Nasdaq: CUE) closed at $28.62 on June 2, 2026, a gain of $4.55 or 18.90% from the prior session, onVolumeof 119,500 shares. Founded in 2014 and headquartered in Boston, Massachusetts, Cue Biopharma is a clinical-stage precision immuno-engineering company developing …
Orchid Island Capital's resurgent profitability marks a turning point for a sector left for dead during the 2022-2023 rate shock. When the Federal Reserve embarked on its most aggressive tightening campaign in four decades, mortgage REITs such as ORC faced a lethal combination of …
Oxford Square Capital presents one of the most visually compelling cases in theBusiness Development Companyspace: a nearly 30% annualised dividend yield available to retail investors seeking income. Yet beneath this surface attraction lies a troubling disconnect. The company's negative earnings per share of -$0.41, …
High-yieldBusinessdevelopment companies often invite scepticism. Many investors have learned through painful experience that eye-catching dividend yields frequently conceal depleting capital bases and distributions funded by returningShareholderEquityrather than operational earnings. The BDC sector's structural incentive to maximize dividend payouts, combined with occasional managerial optimism aboutLoanrecoveries, …
Prospect Capital's headline yield of 17% has undeniable appeal in a world of subdued fixed-income returns. For income-hungry investors, aBusiness Development Companyoffering such returns presents itself as a compelling alternative to traditional bonds or dividend stocks. Yet the sharp divergence between the current indicated …
Please wait processing your request...